glp-1 obesity drug market size 2025 The United States Agonists Weight Loss Drugs & Outlook, 2030 Pharma Giants Bet on Next-Generation

Zepbound was also approved for obstructive sleep apnea (OSA) in December 2024 for adults with moderate-to-severe OSA and obesity

: : 8

In controlled research environments, it is used as a model compound in studies involving redox processes, molecular interactions, and experimental biological frameworks

Important Notice This product is strictly for laboratory and in-vitro research purposes only

J Inherit Metab Dis 21(Suppl 1):138150

These findings together with observed difference in microglia between the expression of ferroptosis-related genes in A-related versus tau-related pathology [18] suggests that vulnerability to ferroptosis might be related to both increased A aggregation and tau hyperphosphorylation